File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Bone Quality In Chinese Postmenopausal Women With Type 2 Diabetes – Impact Of Dipeptidyl Peptidase-4 Inhibitor Usage

TitleBone Quality In Chinese Postmenopausal Women With Type 2 Diabetes – Impact Of Dipeptidyl Peptidase-4 Inhibitor Usage
Authors
Issue Date2018
PublisherWiley Open Access: Various Creative Commons Licenses. The Journal's web site is located at https://onlinelibrary.wiley.com/journal/20401124
Citation
Asia Islet Biology & lncretin Symposium (AIBIS), Seoul, Korea, 2–4 August 2018. In Journal of Diabetes Investigation, 2018, v. 9 n. Suppl. 1, p. 11, abstract no. PO4-1 How to Cite?
AbstractObjectives: To compare the bone quality in type 2 diabetes (T2D) subjects to those without T2D and evaluate the impact of dipeptidyl peptidase-4 inhibitor (DPP4-i) usage on bone quality in T2D subjects, in view of the potential effects of DPP4 and the incretins on bone biology. Methods: We conducted a cross-sectional study of post-menopausal women with T2D subjects recruited from the Hong Kong West Diabetes Registry and non-diabetic subjects from the Hong Kong Cardiovascular Risk Factor Prevalence Study, from November 2016 to June 2018. Subjects with fasting glucose 5.6–6.9 mmol/L, 2 hours post-load glucose 7.8–11.0 mmol/L in oral glucose tolerance test, or HbA1c 5.7–6.4% were classified as pre-diabetes and those with normal glucose tolerance as euglycaemia. Bone mineral density (BMD), vertebral fracture assessment (VFA), and trabecular bone score (TBS) were measured by dual X-ray absorptiometry. BMD and TBS in DPP4-i users and non-users with T2D were compared. Results: Three hundred and sixty subjects were studied: 98 with euglycaemia, 154 with pre-diabetes, and 108 with T2D. Using euglycaemia subjects as reference, pre-diabetes and T2D subjects were significantly older (euglycaemia 60.0 ± 4.4, pre-diabetes 61.8 ± 5.5, and T2D 63.1 ± 5.5 years, p < 0.001) and heavier (euglycaemia 56.1 ± 9.2, pre-diabetes 60.1 ± 10.1, and T2D 62.0 ± 10.5 kg, P < 0.001). Lumbar spine (LS) BMD among T2D subjects was significantly higher than subjects with euglycaemia after adjustment for age, height and weight (0.942 g/cm2 vs 0.876 g/cm2, P = 0.001). TBS among T2D subjects, however, was significantly lower than those with euglycaemia after adjustment for age, height, weight and LS BMD (1.26 vs 1.30, P < 0.001). Among T2D subjects, 47 were DPP4-i users and 61 were non-users. Mean duration of DPP4i usage was 3.1 ± 2.4 years. Age, height, weight, fragility fracture prevalence, HbA1c, duration of diabetes, and frequency of usage of other oral anti-diabetic agents were not significantly different between the two groups. More insulin usage was found among DPP4-i non-users. After adjustment for insulin usage, there was no difference in LS BMD or TBS between DPP4-i users and non-users. Conclusions: Hong Kong Chinese subjects with T2D had lower TBS, an indirect index of bone microarchitecture, but higher BMD when compared with those with euglycaemia. DPP4-i usage, however, did not have significant impact on BMD or TBS among T2D subjects.
Persistent Identifierhttp://hdl.handle.net/10722/300964
ISSN
2020 Impact Factor: 4.232
2020 SCImago Journal Rankings: 1.089

 

DC FieldValueLanguage
dc.contributor.authorLui, TWD-
dc.contributor.authorWoo, YC-
dc.contributor.authorFong, CHY-
dc.contributor.authorChau, VWK-
dc.contributor.authorTsui, AWH-
dc.contributor.authorYeung, KMY-
dc.contributor.authorLam, KSL-
dc.date.accessioned2021-07-06T03:12:41Z-
dc.date.available2021-07-06T03:12:41Z-
dc.date.issued2018-
dc.identifier.citationAsia Islet Biology & lncretin Symposium (AIBIS), Seoul, Korea, 2–4 August 2018. In Journal of Diabetes Investigation, 2018, v. 9 n. Suppl. 1, p. 11, abstract no. PO4-1-
dc.identifier.issn2040-1116-
dc.identifier.urihttp://hdl.handle.net/10722/300964-
dc.description.abstractObjectives: To compare the bone quality in type 2 diabetes (T2D) subjects to those without T2D and evaluate the impact of dipeptidyl peptidase-4 inhibitor (DPP4-i) usage on bone quality in T2D subjects, in view of the potential effects of DPP4 and the incretins on bone biology. Methods: We conducted a cross-sectional study of post-menopausal women with T2D subjects recruited from the Hong Kong West Diabetes Registry and non-diabetic subjects from the Hong Kong Cardiovascular Risk Factor Prevalence Study, from November 2016 to June 2018. Subjects with fasting glucose 5.6–6.9 mmol/L, 2 hours post-load glucose 7.8–11.0 mmol/L in oral glucose tolerance test, or HbA1c 5.7–6.4% were classified as pre-diabetes and those with normal glucose tolerance as euglycaemia. Bone mineral density (BMD), vertebral fracture assessment (VFA), and trabecular bone score (TBS) were measured by dual X-ray absorptiometry. BMD and TBS in DPP4-i users and non-users with T2D were compared. Results: Three hundred and sixty subjects were studied: 98 with euglycaemia, 154 with pre-diabetes, and 108 with T2D. Using euglycaemia subjects as reference, pre-diabetes and T2D subjects were significantly older (euglycaemia 60.0 ± 4.4, pre-diabetes 61.8 ± 5.5, and T2D 63.1 ± 5.5 years, p < 0.001) and heavier (euglycaemia 56.1 ± 9.2, pre-diabetes 60.1 ± 10.1, and T2D 62.0 ± 10.5 kg, P < 0.001). Lumbar spine (LS) BMD among T2D subjects was significantly higher than subjects with euglycaemia after adjustment for age, height and weight (0.942 g/cm2 vs 0.876 g/cm2, P = 0.001). TBS among T2D subjects, however, was significantly lower than those with euglycaemia after adjustment for age, height, weight and LS BMD (1.26 vs 1.30, P < 0.001). Among T2D subjects, 47 were DPP4-i users and 61 were non-users. Mean duration of DPP4i usage was 3.1 ± 2.4 years. Age, height, weight, fragility fracture prevalence, HbA1c, duration of diabetes, and frequency of usage of other oral anti-diabetic agents were not significantly different between the two groups. More insulin usage was found among DPP4-i non-users. After adjustment for insulin usage, there was no difference in LS BMD or TBS between DPP4-i users and non-users. Conclusions: Hong Kong Chinese subjects with T2D had lower TBS, an indirect index of bone microarchitecture, but higher BMD when compared with those with euglycaemia. DPP4-i usage, however, did not have significant impact on BMD or TBS among T2D subjects.-
dc.languageeng-
dc.publisherWiley Open Access: Various Creative Commons Licenses. The Journal's web site is located at https://onlinelibrary.wiley.com/journal/20401124-
dc.relation.ispartofJournal of Diabetes Investigation-
dc.relation.ispartofAsia Islet Biology & lncretin Symposium (AIBIS), 2018-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleBone Quality In Chinese Postmenopausal Women With Type 2 Diabetes – Impact Of Dipeptidyl Peptidase-4 Inhibitor Usage-
dc.typeConference_Paper-
dc.identifier.emailLui, TWD: dtwlui@hku.hk-
dc.identifier.emailWoo, YC: wooyucho@hku.hk-
dc.identifier.emailChau, VWK: chauwk3@hku.hk-
dc.identifier.emailLam, KSL: ksllam@hku.hk-
dc.identifier.authorityLui, TWD=rp02803-
dc.identifier.authorityLam, KSL=rp00343-
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros323127-
dc.identifier.volume9-
dc.identifier.issueSuppl. 1-
dc.identifier.spage11-
dc.identifier.epage11-
dc.publisher.placeAustralia-
dc.identifier.partofdoi10.1111/jdi.12937-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats